Department of Pathology and Immunology, University of Geneva, Geneva University Hospitals, CH-1211 Geneva, Switzerland.
J Neurosci. 2010 Aug 25;30(34):11317-25. doi: 10.1523/JNEUROSCI.1491-10.2010.
Subanesthetic doses of NMDA receptor antagonist ketamine induce schizophrenia-like symptoms in humans and behavioral changes in rodents. Subchronic administration of ketamine leads to loss of parvalbumin-positive interneurons through reactive oxygen species (ROS), generated by the NADPH oxidase NOX2. However, ketamine induces very rapid alterations, in both mice and humans. Thus, we have investigated the role of NOX2 in acute responses to subanesthetic doses of ketamine. In wild-type mice, ketamine caused rapid (30 min) behavioral alterations, release of neurotransmitters, and brain oxidative stress, whereas NOX2-deficient mice did not display such alterations. Decreased expression of the subunit 2A of the NMDA receptor after repetitive ketamine exposure was also precluded by NOX2 deficiency. However, neurotransmitter release and behavioral changes in response to amphetamine were not altered in NOX2-deficient mice. Our results suggest that NOX2 is a major source of ROS production in the prefrontal cortex controlling glutamate release and associated behavioral alterations after acute ketamine exposure. Prolonged NOX2-dependent glutamate release may lead to neuroadaptative downregulation of NMDA receptor subunits.
亚麻醉剂量的 NMDA 受体拮抗剂氯胺酮可在人类中诱导出精神分裂样症状,并在啮齿动物中引起行为改变。氯胺酮的亚慢性给药会通过 NADPH 氧化酶 NOX2 产生的活性氧 (ROS) 导致颗粒蛋白阳性中间神经元的丧失。然而,氯胺酮在小鼠和人类中引起非常迅速的变化。因此,我们研究了 NOX2 在亚麻醉剂量氯胺酮的急性反应中的作用。在野生型小鼠中,氯胺酮引起快速(30 分钟)的行为改变、神经递质释放和大脑氧化应激,而 NOX2 缺陷型小鼠则没有显示出这种改变。反复暴露于氯胺酮后 NMDA 受体亚单位 2A 的表达减少也被 NOX2 缺陷所阻止。然而,NOX2 缺陷型小鼠对安非他命的神经递质释放和行为改变没有影响。我们的结果表明,NOX2 是控制急性氯胺酮暴露后谷氨酸释放和相关行为改变的前额叶皮层中 ROS 产生的主要来源。延长的 NOX2 依赖性谷氨酸释放可能导致 NMDA 受体亚单位的神经适应性下调。